BOLD Audentes Therapeutics Inc.

33.88
+0.93  (+3%)
Previous Close 32.95
Open 33.36
Price To Book 3.67
Market Cap 1,539,577,772
Shares 45,442,083
Volume 367,648
Short Ratio
Av. Daily Volume 438,371

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data to be presented at WMS October 1-5, 2019.
AT132 - ASPIRO
X-Linked Myotubular Myopathy
Phase 1/2 trial to be initiated 4Q 2019.
AT702
Duchenne Muscular Dystrophy (DMD)

Latest News

  1. Edited Transcript of BOLD earnings conference call or presentation 6-Aug-19 8:30pm GMT
  2. Audentes Therapeutics, Inc. (BOLD) Q2 2019 Earnings Call Transcript
  3. Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
  4. Audentes Therapeutics to Participate in Upcoming Investor Conferences
  5. Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019
  6. Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  7. How Does Investing In Audentes Therapeutics, Inc. (NASDAQ:BOLD) Impact The Volatility Of Your Portfolio?
  8. Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD)
  9. Audentes Therapeutics Announces Changes to Senior Management Team
  10. Edited Transcript of BOLD earnings conference call or presentation 7-May-19 8:30pm GMT
  11. Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference
  12. Audentes Therapeutics: 1Q Earnings Snapshot
  13. Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
  14. Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy
  15. Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019
  16. Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility